Table 2.
Clinical inputs.
| N+I [source] | D+T [source] | |
|---|---|---|
| Efficacy inputs | ||
| ORR in % [source] | 67.0% [15] | 69% [6] |
| Median PFS in months [source] | 11.7 [10] | 11.0 [6] |
| Grade 3 and 4 adverse events | N+I pooled RCT AEs in % [sources 9–10] | D+T pooled RCT AEs in % [sources 5–6] |
| Rash | 4.91 | 0.72 |
| Diarrhea | 9.58 | 0.89 |
| Colitis | 9.83 | 0.00 |
| Nausea | 1.97 | 0.18 |
| Vomiting | 2.21 | 0.89 |
| Arthralgia | 0.25 | 0.72 |
| CuSCC | 0.00 | 1.97 |
| Pyrexia | 1.23 | 5.37 |
| Decreased ejection fraction | 0.00 | 2.86 |
| Increase in AST | 8.11 | 1.07 |
| Increase in ALT | 7.13 | 0.72 |
| Constipation | 0.25 | 0.00 |
| Fatigue | 4.42 | 0.72 |
| Pruritus | 1.72 | 0.00 |
| Decreased appetite | 0.98 | 0.00 |
| Hyperthyroidism | 0.25 | 0.00 |
| Headache | 0.74 | 0.00 |
| Hypophysitis | 0.49 | 0.00 |
| Pneumonitis | 0.49 | 0.00 |
| Maculopapular rash | 0.74 | 0.00 |
| Dyspnea | 1.23 | 0.00 |
| Odema peripheral | 0.00 | 0.36 |
| Bleeding events | 0.00 | 0.18 |
| Non-cutaneous malignancies | 0.00 | 0.18 |
| New primary melanoma | 0.00 | 0.18 |
| Hand–foot syndrome | 0.00 | 0.18 |
| Chills | 0.00 | 0.54 |
| Increased lipase | 1.97 | 0.00 |